Pharmaceutical company KalVista Pharmaceuticals Inc (NASDAQ:KALV) stated on Friday that it recorded a net loss of USD3.3m (USD0.22) per basic and diluted share) for the fiscal second quarter ended 31 October 2018.
This marks a rise in earnings when compared with a net loss of USD5.0m (USD0.50 per basic and diluted share) for the same period in 2017.
Revenue of USD5.6m was generated for the three months ended 31 October 2018, up over revenue of USD1.1m for the same period in 2017. Revenue in the three months ended 31 October 2018 consisted of the recognition of a portion of the upfront payment from Merck related to the 2017 agreement.
Research and development (R&D) expenses of USD7.9m were recorded for the three months ended 31 October 2018, a rise versus R&D expenses of USD4.4m for the same period in 2017, which primarily reflects the ongoing clinical trials for KVD001 and KVD900.
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study